Mendus AB (OSTO:IMMU) Additional Paid-In Capital : kr1,454.69 Mil(As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Mendus AB Additional Paid-In Capital?

Mendus AB's quarterly additional paid-in capital increased from Sep. 2024 (kr1,453.81 Mil) to Dec. 2024 (kr1,454.24 Mil) and increased from Dec. 2024 (kr1,454.24 Mil) to Mar. 2025 (kr1,454.69 Mil).

Mendus AB's annual additional paid-in capital increased from Dec. 2022 (kr1,130.64 Mil) to Dec. 2023 (kr1,394.76 Mil) and increased from Dec. 2023 (kr1,394.76 Mil) to Dec. 2024 (kr1,454.24 Mil).

Mendus AB Additional Paid-In Capital Historical Data

The historical data trend for Mendus AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mendus AB Additional Paid-In Capital Chart

Mendus AB Annual Data

Trend

Jun15

Jun16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

1,003.04

1,130.33

1,130.64

1,394.76

1,454.24

Mendus AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															1,395.35	1,453.27	1,453.81	1,454.24	1,454.69

Mendus AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Mendus AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Mendus AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Mendus AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mendus AB (OSTO:IMMU) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

1YG0:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, 11153

Website

https://www.mendus.com

Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. Company Pipeline includes: Vididencel, Ilixadencel, Preclinical.